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ABSTRACT
Objective To critically appraise the quality of published 
systematic reviews (SRs) of randomised controlled trials 
(RCTs) in tendinopathy with regard to handling and 
reporting of results with special emphasis on strength of 
evidence assessment.
Data sources Medline from inception to June 2020.
Study eligibility All SRs of RCTs assessing the 
effectiveness of any intervention(s) on any location of 
tendinopathy.
Data extraction and synthesis Included SRs were 
appraised with the use of a 12- item tool devised by 
the authors arising from the Preferred Reporting Items 
in Systematic Reviews and Meta- Analyses statement 
and other relevant guidance. Subgroup analyses were 
performed based on impact factor (IF) of publishing 
journals and date of publication.
Results A total of 57 SRs were included published in 38 
journals between 2006 and 2020. The most commonly 
used risk- of- bias (RoB) assessment tool and strength of 
evidence assessment tool were the Cochrane Collaboration 
RoB tool and the Cochrane Collaboration Back Review 
Group tool, respectively. The mean score on the appraisal 
tool was 46.5% (range 0%–100%). SRs published in 
higher IF journals (>4.7) were associated with a higher 
mean score than those in lower IF journals (mean 
difference 26.4%±8.8%, p=0.004). The mean score of 
the 10 most recently published SRs was similar to that of 
the first 10 published SRs (mean difference 8.3%±13.7%, 
p=0.54). Only 23 SRs (40%) used the results of their RoB 
assessment in data synthesis and more than half (n=30; 
50%) did not assess the strength of evidence of their 
results. Only 12 SRs (21%) assessed their strength of 
evidence appropriately.
Conclusions In light of the poor presentation of evidence 
identified by our review, we provide recommendations to 
increase transparency and reproducibility in future SRs.
INTRODUCTION
The ever- expanding arsenal of treat-
ment regimes for tendinopathy can be 
overwhelming to the treating healthcare 
professional. New treatments continuously 
emerge and so do research studies that aim to 
assess their effectiveness. The most powerful 
tool that evidence- based medicine has to 
offer remains systematic reviews (SRs) of 
randomised controlled trials (RCTs), which 
constitute the highest level of evidence and 
are therefore often used to inform guidelines 
and guide clinical practice.1
Unlike a narrative review, which is purely a 
summary of a proportion of (or all) the avail-
able studies on a given topic without assessing 
the quality of the included evidence, an SR is 
expected to include all the relevant evidence 
which is comprehensively and thoroughly 
appraised and presented with qualitative or 
quantitative syntheses and accompanying 
Summary box
What is already known?
 ► The increasing number of available treatment mo-
dalities for tendinopathy can be overwhelming to the 
treating healthcare professionals.
 ► Systematic reviews (SRs) of randomised controlled 
trials provide the highest level of evidence and guide 
application of research findings to clinical practice.
 ► There are several strength of evidence assessment 
tools used in tendinopathy SRs.
 ► The use of strength of evidence assessment results 
in data synthesis is associated with confusion and 
inconsistency.
What are the new findings?
 ► More than half of the SRs did not assess the strength 
of evidence in their results.
 ► Only 21% of SRs assessed their strength of evidence 
appropriately.
 ► Authors who publishing SRs on the management of 
tendinopathy should become familiar with strength 
of evidence assessment tools and apply them ap-
propriately in their data synthesis and presentation.
 ► We provide recommendations to increase transpar-
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strengths of evidence.2 For reliable, clinically relevant 
conclusions to be reached, the potential limitations of 
the included studies need to be considered.3 What deter-
mines the ‘quality’ of a study remains poorly defined but 
should relate to the extent to which its design, conduct, 
analysis and presentation are appropriate to answer its 
research question.3 Generally, study quality assessment 
includes a combined assessment of its internal validity 
(freedom from bias), external validity (generalisability/
applicability) and precision (freedom from random 
error)3 (online supplemental figure 1). The Cochrane 
group, which produce some of the highest quality SRs, 
recommend emphasising the internal validity when 
assessing the quality of a study, reflected by the risk- of- bias 
assessment (RoB) tool they have produced.3 However, 
external validity and precision should not be overlooked.
Assessing the strength of evidence (also known as 
‘certainty’, ‘quality’, ‘level’ or ‘grade’ of evidence) is 
closely interlinked with RoB assessment and is a process 
which is commonly overlooked by many SRs. Together 
with a meticulous methodology and comprehensive RoB 
assessment, this is what distinguishes a SR from other 
types of review articles. Assigning a strength of evidence 
to a finding is as important as the finding itself. Strength 
of evidence should accompany every assessed outcome 
measure within an SR for every assessed follow- up time 
period.4 5 A result with a low strength of evidence differs 
substantially from that with a high level of evidence in 
terms of its applicability to clinical practice; further 
research is likely to change the former but not the 
latter.6 Equally, the strength of evidence can be high in 
an outcome measure and low in another, and high for a 
certain follow- up but period and low for another.
An SR should be transparent and reproducible, and 
subjectivity should be kept to a minimum.7 Firm guidance 
on conducting SRs does not exist and several parameters 
are left to the judgement of the authors. In an attempt 
to optimise the quality of SRs, the Preferred Reporting 
Items in Systematic Reviews and Meta- Analyses (PRISMA) 
group have published evidence- based guidance, 
including a 27- item checklist.8 Similarly, the A MeaSure-
ment Tool to Assess systematic Reviews (AMSTAR) group 
have published a critical appraisal tool for SRs aiming to 
help the reader/appraiser make conclusions about its 
quality.9 The aim of the former in particular is to help 
authors improve the reporting of SRs and meta- analyses 
of randomised trials and it is considered the gold stan-
dard for the authorship of SRs. However, summarising the 
strength of the presented evidence, which is mentioned 
in one of its items, does not receive sufficient attention in 
most SRs. Moreover, recent debate in the Lancet argues 
that the findings of SRs may be flawed as they often 
include poor- quality studies that should have not been 
published in the first place.10
Our aim was to critically appraise the quality of 
published SRs of RCTs in tendinopathy, with emphasis 
on handling and reporting of results and especially 
assessment of the strength of evidence, which is often 
overlooked. We provide recommendations for authors of 
future SRs aiming to optimise data synthesis, reporting 
and summarising the strength of evidence. The present 
review is also intended for readers of SRs, who need to 
critically appraise their quality before reaching conclu-
sions about their findings, and finally it can be used 
by reviewers and editors of journals when assessing 
submitted SRs for publication.
METHODS
Eligibility
Eligible articles assessed the effectiveness of any interven-
tion(s) on tendinopathy (any type), identified themselves 
as an SR and/or meta- analysis and only included RCTs. 
Reviews including a mixture of randomised studies and 
other types of studies (non- randomised clinical trials, 
cohort studies, case series, etc) and those assessing the 
effectiveness of interventions on tendinopathy and other 
conditions were excluded. Only articles published in 
English were included in patients over 16 years of age. No 
criteria were used regarding the following parameters: 
publication date, journal type, type of tendinopathy and 
intervention, outcome measures and length of follow- up.
Search strategy: screening
A literature search was conducted by the first author 
via Medline in June 2020 with the following Boolean 
operators in ‘All Fields’: “((systematic review) OR (meta- 
analysis) AND (tendin*) AND (randomi*)). For all 
eligible articles, the reference lists and PubMed’s ‘similar 
articles’ list were screened to identify potentially eligible 
articles that may have been missed at the initial search. 
Figure 1 (PRISMA flow chart) illustrates the article 
screening process.
The initial search returned a total of 207 articles. 
After exclusion of non- eligible articles according to our 
predefined criteria and inclusion of articles identified 
from reference screening, 57 reviews were included in 
our appraisal.
Data extraction: handling
The included articles were read by the first author and 
their key characteristics were tabulated in Microsoft 
Word. Each article was then reread and appraised with 
regard to the handling and reporting of results based on 
our prespecified appraisal tool.
Appraisal tool: rationale and explanation of items
We developed a 12- item appraisal checklist based on guid-
ance from the PRISMA checklist predominantly, as well 
as other key documents, namely the Grading of Recom-
mendations Assessment, Development and Evaluation 
(GRADE) tool, the AMSTAR checklist and the Cochrane 
Collaboration Back Review Group.4 5 8 9 We highlight 
that our tool was created merely for the purposes of 
the present review, it does not intend to appraise SRs 
as a whole and it cannot replace other tools such as the 
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be used in conjunction with them. It intends to assess 
data synthesis and presentation without considering 
other important methodological aspects (eg, search 
strategy, screening, inclusion criteria). Each item receives 
either a ‘0’, ‘1’ or ‘2’ except for four items (2, 4, 11, 12) 
which only receive ‘0’ or ‘1’. The maximum score is 20 
for SRs that include both qualitative and quantitative 
analyses and 18 for those including one or the other. The 
tool is intended to be used as a checklist rather than a 
scoring system, however, scoring was used in the present 
review for the purposes of subgroup comparisons. The 12 
items are divided into the following three categories and 
a description of how the tool was used is provided below:
ROB assessment
Item 1: The RoB assessment of each included RCTs, with 
or without an ‘overall risk’ for each study, needs to be 
used somehow for summarising the strength of evidence, 
which is its primary purpose, and this needs to be 
explained in the methods. This can be through subgroup 
analyses, for example, only synthesising results of studies 
with low overall RoB (which is indirectly associated with 
strength of evidence assessment).
Item 2; RoB should be assessed for each outcome 
measure separately to determine the strength of 
evidence of the results for that specific outcome measure. 
Assessing RoB on an outcome measure level rather than 
a study level becomes particularly important when the 
study includes patient- reported measures and measures 
assessed directly by another assessor. With the former, 
if the participants are not blinded then automatically 
the assessment of outcome measures cannot be blinded 
either as the assessor is the participant his/herself. For 
non- patient- reported measures, regardless of blinding of 
participants, the blinding of assessment depends solely 
on whether the assessor (researcher) is blinded or not. 
If RoB is assessed on a study and not outcome level this 
should be stated in the methods with a justification (ie, 
all outcome measures were patient reported or partici-
pants of all studies blinded, etc). For SRs including one 
outcome measure only, this item was not scored.
Pooling of results
Item 3: The principal summary measures for each 
included outcome measure need to be stated in the 
methods. For quantitative analyses, where outcome 
measures are continuous, a justification needs to be 
provided for the use of (raw) mean differences (MD) and 
not standardised MD (SMD) and vice versa (ie, identical 
or different outcome measure tools used across studies, 
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respectively). Similarly, for dichotomous outcomes, the 
authors should state in the methods whether OR or rela-
tive risks (RR) were used.
Item 4: An SR without a meta- analysis should ideally 
have some quantitative summary measures (ie, MD, 
SMD, OR or RR with accompanying CI) to demon-
strate the treatment effect of the assessed intervention 
over the comparator. Where results are pooled only 
based on direction of effect (ie, increased, decreased or 
unchanged), this needs to be stated in the methods with 
a justification. If pooling is not possible and results are 
only described narratively, the reason should be stated 
(usually substantial clinical heterogeneity); in such cases, 
we question whether the article should be identified as 
an SR.
Item 5: When meta- analyses are performed, the model 
used needs to be stated (ie, fixed effects or random 
effects) with a justification and the statistical heteroge-
neity assessment (usually χ2 and/or I2 test) and how it was 
used in data syntheses. Sensitivity and subgroup analyses 
should also be pre- defined in the methods.
Items 6 and 7: Results should only be pooled for similar 
follow- up time periods which should be prespecified in 
the methods. Traditionally these are short term, mid term 
and long term. The range of these should be defined by 
the authors in the methods based on the population, 
outcome measures and interventions. Equally, assessed 
outcome measures should be predefined (usually as part 
of PICOS).
Item 8: A statement needs to be included in the section 
explaining how the authors dealt with missing data, 
which are usually methodological details of the included 
studies needed for the RoB assessment and descrip-
tive statistics for quantitative analyses. For both, ideally 
attempts should be made to contact the authors of the 
RCTs for retrieval of the missing data and this should be 
stated. If significant statistical data of included studies 
cannot be retrieved (ie, sample sizes and means) these 
studies should be excluded from quantitative analyses; if 
variability statistics (SD) are missing, the authors have the 
option to impute these using data from other RCTs and 
the imputation method used should be described.
Strength of evidence assessment
Items 9–12: Assigning a strength of evidence to a result 
is an essential part of an SR and it should be determined 
separately for each predefined outcome measure at each 
predefined follow- up time period. By and large this is 
determined based on the overall quality of the included 
studies and the extent of consistency of their findings 
with considerations of other limitations across studies. 
Regardless of the tool used, which should be included in 
the methods with a brief description, the authors should 
clearly describe how data were synthesised with regard 
to assessing the strength of evidence, stating how RoB 
assessment was used and what other paramaters/limita-
tions were considered. Excluding the GRADE tool, which 
has clear instructions on how specific intrastudy (RoB) 
and interstudy (inconsistency, imprecision, indirectness, 
publication bias) limitations should be handled, the 
authors should clarify: (1) whether study quality was deter-
mined based on RoB only or whether other parameters 
were taken into account (eg, precision, external validity) 
with a justification; (2) how consistency was defined (ie, 
based on direction of effect, overlap of CIs, etc). When 
there is some clinical heterogeneity across studies but 
not sufficient to preclude pooling of results, this should 
be accounted for and used as part of the strength of 
evidence assessment. More specifically, authors should 
include a statement to show that they have considered/
assessed for potential differences in included popula-
tions, interventions and outcome measures used across 
studies and how they think this might affect the strength 
of the evidence of their results. Finally, a statement in the 
methods should be included to acknowledge the risk of 
publication bias and whether it was assessed formally. A 
funnel plot should be constructed and inspected/accom-
panied with the appropriate statistical tests (ie, Egger’s 
test) where the results of a considerable number of studies 
(usually 10 or more) were pooled. For SRs including one 
outcome measure only, item 11 was not scored.
STATISTICAL ANALYSIS: SUBGROUP ANALYSIS
A mean score was calculated for all appraised SRs. 
Subgroup analyses included comparisons of mean 
scores of reviews published in a higher versus a lower 
impact factor (IF) journal (mean IF of included 
journals used as cut- off). The latest journal IFs were 
obtained from the journal’s official website. For jour-
nals without an IF, a score of 0 was given. Finally, the 
mean score of the first 10 published SRs was compared 
with that of the last 10 published. All comparisons 
were performed with two- tailed independent samples 
t- tests in Graphpad Prism V.8. Significance levels were 
set at p<0.05.
RESULTS
A total of 57 articles published in 38 journals were 
included in our review.11–67 Publication date ranged 
from 2006 to 2020, journal IFs ranged from 0 to 
59.102 (mean 4.7, median 2.55). The journal with 
the most published SRs of RCTs on tendinopathy 
interventions was the British Journal of Sports Medi-
cine (n=6) and the most commonly investigated 
tendinopathy in isolation was shoulder (calcific and 
non- calcific; n=24), followed by lateral elbow (n=10) 
and patellar (n=8). A total of 10 reviews assessed tend-
inopathy as a generic condition and assessed the same 
intervention(s) on more than one location of tend-
inopathy and two reviews included RCTs of ‘lower 
limb tendinopathies’. The most frequently assessed 
intervention in isolation was extracorporal shock- 
wave therapy (n=10), followed by platelet- rich plasma 
(n=7), however, several SRs included more than one 
‘related’ intervention (ie, ‘non- surgical therapies’, 
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Online supplemental table 1 provides an overview 
of the included SRs with relevant characteristics and a 
summary of their key findings.11–67 Table 1 shows our 
appraisal tool and the results of the appraisal for each 
SR with overall scores both for each SR and for each 
item (explanation of the items in table caption).11–67
The most commonly used RoB assessment tools in 
the included SRs were the Cochrane Collaboration 
tool3 67 (n=30) and the PEDro scale68 69 (n=14). Of 
the 52 SRs that conducted an RoB assessment, only 
23 (44%) explained how that would be used in data 
synthesis and 27 (52% reviews did not use their RoB 
assessment results in data synthesis at all. Where 
assessment of strength of evidence was predefined 
and applied, the most frequently used tools were the 
Cochrane Back Review Group tool4 (n=10) and the 
GRADE tool5 (n=6). Other tools for assessing strength 
of evidence used included the National Health and 
Medical Research Council (NHMRC) tool70 and that 
devised by the Cochrane musculoskeletal group.71 
More than half of the included reviews (n=30; 53%) 
did not use or even mention quality/strength/level 
of evidence in their manuscript, while another nine 
included an arbitrary statement of a level of evidence 
in their discussion or conclusion without explaining 
the process of determining this anywhere in the manu-
script. Of the remaining 18 reviews which described 
the use of a tool to assess the strength of evidence in 
their methods, only 12 of them used it appropriately 
according to the criteria/instructions of the tool (and 
to a lesser extend the judgement of the authors of the 
present review).
The items of our tool with the lowest overall score 
were item 2 (2/52; 4%) and item 11 (8/52; 15%), 
which both relate to whether assessments (RoB and 
strength of evidence) were conducted on an outcome 
measure and not study level. Those with the highest 
were item 6 (65/68; 95%) and item 4 (45/57; 79%).
The mean score of the included SRs on our appraisal 
tool was 46.5% (range 0%–100%). Subgroup analyses 
showed that those published in higher IF journals 
(>4.7; n=10) had a significantly higher mean score 
than those (n=47) in lower IF journals (68.3% vs 
41.8%, difference 26.5%±8.8%, p=0.004) (figure 2A). 
The first 10 published SRs (2006–2012) had a slightly 
lower mean score (48.3%) than the 10 most recently 
published ones (2019–2020; 56.6%) with a statisti-
cally insignificant difference (8.3%±13.7%, p=0.54; 
figure 2B).
DISCUSSION
Having critically analysed several published SRs of 
RCTs in the management of tendinopathy, we found 
that the results of more than half of the included SRs 
were presented without an accompanying strength 
of evidence assessment, which is as important as 
the results themselves for guiding clinical practice. 
Additionally, a substantial proportion of results 
from the included reviews were presented with levels 
of evidence assigned to them arbitrarily without 
described and reproducible methods. Our find-
ings imply that the majority of SR authors may not 
be familiar with conducting a strength of evidence 
assessment and its practical implementation. The 
other interesting finding was that half of the reviews 
that performed an RoB assessment did not make any 
use of it; we assume this is because they either do not 
understand the purpose of RoB assessment and they 
only conducted an RoB assessment knowing that it 
is a prerequisite for an SR, or they left the interpre-
tation of the link between their RoB assessment and 
the undetermined strength of evidence open to the 
reader.
As an example of the disparity in assessing the 
strength of evidence, a recent SR of SRs on the clin-
ical management of tendinopathy summarised all the 
available evidence concluding that eccentric exercise 
with or without other treatments is the best available 
intervention.72 Unlike our appraisal which yielded 
poor overall results, their assessment of quality of the 
included SRs was overall high. This is predominantly 
because the appraisal tool they used (AMSTAR) does 
not take into account the importance of determining 
the strength of evidence for the findings. Addition-
ally, having used very similar criteria to our review, 
performing searches in many more databases, and 
even having included some SRs with a mixture of 
randomised and non- randomised studies, they only 
included 25 SRs as opposed to 57 included in ours.
The widely used PRISMA checklist is regarded as 
the gold standard for the conduct and reporting of 
SRs.8 Its 27 items cover all sections of an SR, including 
the title (1 item), abstract (1 item), introduction (2 
items), methods (12 items), results (7 items), discus-
sion (three items) and funding (1 item). The purpose 
of the checklist, as its name suggests, is to increase 
transparency in the reporting of SR and meta- analyses, 
however, the conduct of some of its items remains very 
subjective. This is especially true for the assessment of 
strength of evidence, which, according to the check-
list, should be performed for each outcome measure 
in the discussion section, however, further guidance/
instructions are not provided.8 We argue that details 
of the process of strength of evidence assessment 
should be included in the methods section of an SR 
to increase transparency and reproducibility.
Recommendations
In the following paragraphs, we provide recommen-
dations for what we believe are the most subjective 
and poorly understood aspects of an SR, aiming to 
increase transparency, reproducibility and hence 
the quality of the SR and the confidence in its find-
ings. According to the National Institute for Health 
Research, authors should only identify their article as 
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synthesis methods would, in theory, permit the repli-
cation of the review by others’.7 All recommendations 
arise from key documents guiding the conduct of SRs: 
the PRISMA checklist, the Cochrane handbook, the 
GRADE handbook and the Cochrane Collaboration 
Back Review Group guidance.4 8 67 73
RoB assessment
We highlight once again that an RoB assessment is the 
most important part of but not exactly synonymous to 
study quality assessment. Where the strength of evidence 
assessment tool used relies on study quality (eg, Cochrane 
Back Review Group tool), the authors should clarify if 
they only use RoB assessment as an extension of study 
quality. Finally, RoB assessment should be performed on 
an outcome measure level, not a study level, especially 
when the study includes both patient- reported outcomes 
and outcomes directly measured by study faculty.
We recommend the use of the revised RoB assessment 
tool recently published by the Cochrane Collaboration 
(RoB 2) as it is more standardised and reproducible 
with clear instructions on how it should be used and 
less subjectivity.74 Most importantly, the creators include 
instructions for determination of overall RoB for each 
study which will substantially increase its correct imple-
mentation in data syntheses in SRs.74 Alternatively, the 
RCT methodology checklist published by the Scottish 
Intercollegiate Guideline Network75 could also be used, 
especially where the Cochrane Collaboration Back 
Review Group tool is used for strength of evidence assess-
ment (see below). Importantly, the checklist finishes with 
an ‘overall assessment of the study’, which is the equiva-
lent of RoB 2’s ‘overall RoB’ and can be used directly for 


























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Figure 2 Subgroup analyses comparing the mean scores 
of reviews published in a higher versus a lower impact factor 
(IF) journals. Those published in higher if journals (>4.7; n=10) 
had a significantly higher mean score than those (n=47) in 
lower if journals (68.3% vs 41.8%, difference 26.5%±8.8%, 
p=0.004) (A). The first 10 published SRs (2006–2012) had a 
slightly lower mean score (48.3%) than the 10 most recently 
published ones (2019–2020; 56.6%) with a statistically 
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Pooling of results
All SRs should include pooling of results to make conclu-
sions about an overall treatment effect where clinical 
heterogeneity allows.8
In the absence of significant clinical heterogeneity, 
results should be pooled quantitatively where there are 
two or more studies assessing the same interventions, 
ideally with pairwise meta- analyses that improve preci-
sion.8 67 In the context of tendinopathy interventions, 
unless the settings, participants and interventions are 
almost identical (clinical homogeneity), we suggest the 
use of a random- effects and not a fixed- effects model for 
meta- analyses.67 Alternatively, if the authors of the review 
believe that the included studies are largely homogenous 
clinically, the choice of the model should be made on the 
basis of statistical heterogeneity, which needs to be quan-
tified with a statistical test (eg, fixed- effects for I2 <50%, 
random- effects for I2 >50%).76 Forest plots should be 
presented for each comparison with their accompanying 
MD/SMD (continuous outcomes) or OR/RR (dichoto-
mous outcomes) and 95% CI, p value and heterogeneity 
test (eg, I2 statistic).8 67 In the presence of significant statis-
tical heterogeneity (eg, >50%), attempts should be made 
through sensitivity analyses for a single study that may be 
responsible for the high heterogeneity to be identified 
and removed from the comparison before the analysis is 
rerun.67 76 No more than one study should be removed. 
Where the I2 test is substantial (>75%) despite sensitivity 
analyses, the meta- analysis should be abandoned.76
For qualitative reviews, where numerical values of 
treatment effects cannot be obtained and pooled quanti-
tatively, pooling should be performed based on direction 
of effect for studies assessing the same interventions, even 
in the presence of some clinical heterogeneity, which 
should be recognised and accounted for in the strength 
of evidence assessment.4 The statistical significance test 
result reported by the authors of the RCT for intergroup 
differences should be accounted for when pooling results 
(ie, a statistically insignificant difference between the two 
groups will count as ‘no difference’). A table with pooled 
results and accompanying strengths of evidence should 
be used to make the pooling clearer to the reader (eg, 
table 1).
Data should only be combined for similar, predefined 
follow- up time periods, that is, short term, mid term and 
long- term.4 These periods should ideally be subdivided 
especially when their range is large and when there are 
sufficient data for pooling. For instance, for a predefined 
‘short- term follow- up’ at 0–12 weeks, this can be subdi-
vided into early short term (eg, 2–6 weeks) and late short 
term (7–12 weeks).
Strength of evidence assessment
The two tools most frequently used in our included 
SRs (Cochrane Back Review Group and GRADE) differ 
substantially and we advocate the preferential use of 
one over the other in specific situations.4 73 Unlike the 
Cochrane Back Review Group tool, the intention of 
which is to allocate a ‘level’ (strength) of evidence to data 
pooled qualitatively, the GRADE tool is very comprehen-
sive, it considers limitations across studies, not only within 
studies and is very transparent.4 73 The main difference of 
the two tools lies within the fact that the Cochrane Back 
Review Group tool relies on quality assessment of each 
study; the GRADE tool advocates assessing the quality of 
the body of the pooled evidence, not individual studies. 
The former is primarily based on direction of effect (ie, 
qualitative synthesis of results) and the latter on quanti-
tative analyses.
Considering the nature and the intention of these 
two tools, we recommend the use of the GRADE tool 
for all SRs where comparisons of interventions include 
any type of quantitative analyses (with or without a meta- 
analysis) and the Cochrane Back Review Group where 
only direction of effect is used for pooling of results (ie, 
qualitative analysis only). However, when the Cochrane 
Back Review Group tool is used, in addition to RoB 
assessment which should be used to determine the level 
of evidence for each outcome measure, we recommend 
using imprecision, indirectness of evidence and publica-
tion bias (where appropriate) to downgrade the level of 
evidence in a similar fashion to the GRADE tool. Besides, 
van Tulder et al state in their original publication that 
in addition to methodological quality of the original 
studies, participants, interventions and outcomes should 
also be taken into account when levels of evidence are 
attributed to qualitative analyses.4 Table 2 and table 3 can 
be used to increase transparency of the methods used 
for assessing the strength of evidence. Alternatively, the 
‘summary of findings’ table suggested by GRADE can be 
used, separately for each outcome measure and follow- up 
time period with explanations for each downgrading of 
the evidence.73
Neither the GRADE tool nor the Cochrane Collaboration 
Back Review Group tool come without disadvantages.4 5 Despite 
GRADE’s comprehensiveness, which includes a detailed 
Table 2 Suggested pooling of results for qualitative analyses (example)
Comparison Follow- up Study Outcome measure 1 Outcome measure 2 Outcome measure 3
Intervention 1 versus 
intervention 2
  Short/mid/long term Author (year) ↓ ↓ ↓
Author (year) ↓ ↔ ↓
Author (year) ↓ ↑ –
Overall intervention 1 versus intervention 2
(evidence level)
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handbook providing explanation and instructions of all the 
steps, its conduct requires decisions that are based on the 
assessor’s judgement, for example, determining whether the 
overall RoB for an outcome measure is high or low when 
pooling studies with overall high and low RoB and deciding 
whether the magnitude of inconsistency and indirectness is 
significant enough to justify downgrading the evidence.73 
Nevertheless, we believe that it is the most thorough and 
transparent tool for strength of evidence assessment and it 
should be used preferentially over other tools where possible. 
Similarly, the Cochrane Collaboration Back Review Group 
tool requires subjective decisions for the determination of 
the strength of evidence for a result, primarily due to its 
lack of definition for its two main criteria; (1) consistency of 
results and (2) study quality. Additionally, unlike GRADE, it 
does not consider ‘between- study’ limitations, such as impre-
cision of results and indirectness of evidence.
An SR is no small undertaking and should not make for 
an easy publication. Future authors who only intend to 
summarise the available evidence without a comprehen-
sive quality assessment and strength of evidence assessment 
should strongly consider identifying their reviews as narra-
tive, not systematic. Admittedly, strict word counts and other 
restrictions from journals undoubtedly have a negative influ-
ence on the quality of the published SRs; we, therefore, invite 
the editors of publishing journals to either loosen restrictions 
for submitted articles or discuss word counts and accompa-
nying material (tables/figures) with authors on a case- by- case 
basis. Publication of narrative reviews should also become an 
option in all publishing journals.
CONCLUSIONS
In the present review, we have demonstrated that the majority 
of SRs of RCTs in tendinopathy do not assess the strength of 
evidence of their results and this can substantially influence 
their application to clinical practice. In the future, authors 
implicated in producing and publishing SRs on the manage-
ment of tendinopathy should become familiar with strength 
of evidence assessment tools and apply them appropriately 
in their data synthesis and presentation. Finally, relevant 
guidance documents should emphasise the importance of 
strength of evidence assessment and provide more detailed 
instructions for its conduct to increase consistency and trans-
parency.
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Supplementary Figure 1: Useful definitions 
 
Study quality: the extent to which its design, conduct, analysis and 
presentation were appropriate to answer its research question. Consists 
of internal validity, external validity and precision 
 
Quality/strength of evidence: one’s confidence in the estimates of 
effect. This is usually “high”, “moderate”, “low”, “very low”, “limited” or 
“conflicting” depending on the grading tool used  
 
Internal validity of a study: freedom from methodological bias (extent 
to which confounding factors were minimised); i.e. did the study use a 
sound methodology? 
 
External validity of a study: the extent to which the results of the study 
are applicable and generalisable to the target population in clinical 
practice. This depends on the population, interventions and outcome 
measures used in studies and how they relate to those in clinical practice.  
 
Precision: freedom from random error, i.e. the likelihood of the results of 
the studies to represent the true effect of the tested intervention. 
Generally, the smaller the population and the fewer the events in a study, 
the greater the imprecision (reflected by a wider confidence interval). 
Similarly, in the context of a systematic review/meta-analysis, the wider 
the confidence interval of the estimate of the treatment effect the higher 
the imprecision of the pooled evidence.  
  
Directness of evidence: evidence arising from direct comparisons of 
interventions, delivered to the populations in which we are interested, 
and measures the outcomes important to patients. The four sources of 
indirectness are: differences in populations, differences in interventions, 
differences in outcome measures (surrogate outcomes) and indirect 
comparisons. Indirectness of evidence is synonymous to clinical 
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heterogeneity when it is assessed on an “across studies” (“inter-study”) 
level and external validity when on a “within studies” (“intra-study”) level. 
 
Consistency of results: the extent to which all included studies have 
the same underlying effect. In the context of a systematic review/meta-
analysis, inconsistency of results across studies is synonymous to 
statistical heterogeneity, which is usually quantified with the I2 statistic. 
The I2 statistic quantifies the proportion of the variation in point estimates 
due to among-study differences.  
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quality of 
evidence; 
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Cochrane None Manual therapy 
may decrease 
pain but it is 











Shoulder 10 Exercise Work-
related 
outcomes 














Shoulder 6 TENS Pain, ROM 
(not pre-
defined) 
Cochrane None Inconclusive 















Cochrane None Therapeutic US 
administered 
with exercise no 
Yes 
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Pain Cochrane None Some injection 
therapies can 
be effective 
(e.g. BOTOX and 


























Am J Sports 
Med  
(6.093) 
All 18 PRP Pain Cochrane None Good evidence 
to support 
single injection 
of PRP under US 
guidance 
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improveme
nt, function 
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injection 
superior to PRP 
in short-term 
Yes 
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but PRP more 
effective in 
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Cochrane None Corticosteroid 
effective in 




superior in the 
long-term 
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injections 
superior to 
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Achilles 4 Laser therapy  Function, 
pain, QoL, 
Cochrane GRADE Inconclusive 
due to low 
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or without laser 
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All 5 PRP Pain, 
functional 
disability 
Cochrane None PRP provided 
no more clinical 
benefit than 
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superior to 
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Suppl. Table 1: Characteristics of included systematic reviews and their key findings. ESWT, extracorporeal shock-wave therapy; GTN, 
glyceryl trinitrate; PRP, platelet-rich plasma; ROM, range of movement; TENS, transcutaneous electrical nerve stimulation; QoL, quality of life; 
US, ultrasound    
*one non-randomised trial included 
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Supplementary Figure 2: Useful statistical formulas 
 




Mean1 (SD1) = Mean (SD) at baseline  
Mean2 (SD2) = Mean (SD) at follow up 
* Not the same as mean difference (MD), which is the mean value of the combined 
differences in means 
 
 







SD1 = SD from study 1, SD2 = SD from study 2 etc  
n1 = sample size from study 1, n2 = sample size from study 2 etc  











N=the sample size required in each of the groups  
x1 – x2 = minimal clinically relevant difference (defined by authors) 
SD2 = population variance (SDpooled can be used) 
a = 1.96 (for 5% type I error) 
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Required statistic Available statistic Conversion 
SD 
SEM SD = SEM x √𝑛 
IQR SD = IQR / 1.35 
Range SD = length of range / 4 
CI (length of CI / 3.92) x √𝑛 
95% CI 
Mean1 (SD1) and mean2 
(SD2) 
CI = mean2 – mean1 ± 
1.96(SDpooled / n) 
Mean Median Mean = Median 
 
Useful statistical conversions. CI, confidence interval; IQR, interquartile range; 
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